Estrogen receptor b (ERb) is emerging as a critical factor in understanding prostate cancer biology. Although reduced in prostate cancer above Gleason grade 3, ERb is a potential drug target at the initial stage of the disease. In human prostate cancer cells, we found that ERb causes apoptosis by increasing the expression of pro-apoptotic factor p53-upregulated modulator of apoptosis (PUMA), independent of p53, but dependent on the forkhead transcription factor class-O family member, FOXO3a. FOXO3a has previously been shown to induce PUMA after growth factor withdrawal and inhibition of the Akt pathway. Surprisingly, the phosphorylation of FOXO3a remained unchanged, while the mRNA and total protein levels of FOXO3a were increased in response to ERb expression or treatment of PC3, 22Rv1 and LNCaP cells with the ERb-specific ligands 3b-Adiol (5a-androstane-3b,17b-diol), DPN (diarylpropionitrile) or 8b-VE2 (8-vinylestra-1,3,5 (10)-triene-3,17b-diol). Knockdown of FOXO3a or ERb expression abolished the increase of PUMA in response to 3b-Adiol in LNCaP and PC3 cells, suggesting that FOXO3a mediates the apoptotic effect of 3b-Adiol-activated ERb. Moreover, the ventral prostate of ERb À / À mice had decreased expression of FOXO3a and PUMA compared with the ERb þ / þ mice, indicating a relationship between ERb and FOXO3a expression. The regulation of FOXO3a by ERb in normal basal epithelial cells indicates a function of ERb in cell differentiation and maintenance of cells in a quiescent state. In addition, the expression of ERb, FOXO3a and PUMA is comparable and higher in benign prostatic hyperplasia than in prostate cancer Gleason grade 4 or higher, where there is substantial loss of ERb, FOXO3a and PUMA. We conclude that ERb induces apoptosis of prostate cancer cells by increasing transcription of FOXO3a, leading to an increase of PUMA and subsequent triggering of apoptosis via the intrinsic pathway involving caspase-9. Furthermore, we conclude that ligands specifically activating ERb could be useful pharmaceuticals in the treatment of prostate cancer.
INTRODUCTION
Prostate cancer is the leading cause of cancer-related death in men in the United States. 1 Although the frontline treatment remains androgen deprivation, the tumor eventually becomes resistant to anti-androgen therapy. In the healthy prostate, androgen withdrawal causes apoptosis by a process called androgenwithdrawal-induced apoptosis, which helps to maintain tissue homeostasis. 2 In advanced prostate cancer androgen-withdrawalinduced apoptosis is abrogated, leading to androgen-independent prostate cancer.
The p53-upregulated modulator of apoptosis (PUMA) is a potent pro-apoptotic factor, which belongs to the Bcl-2 homology 3-only subgroup. PUMA was initially identified as a p53 target gene and is induced upon genotoxic stress through induction of p53. 3 PUMA can also be upregulated in a p53-independent manner by the forkhead transcription factor class-O family member, FOXO3a, upon withdrawal of cytokine/growth factor signaling. 4 The apoptotic action of FOXO3a is inhibited by Aktmediated phosphorylation, upon which the FOXO3a protein interacts with a 14-3-3 member and is translocated to the cytoplasm, where it undergoes proteasomal degradation. The phosphoinositide 3-kinase/Akt pathway is upregulated in cancer, either due to a gain-of-function mutation in the phosphoinositide 3-kinase enzyme or by deletion mutation of PTEN (phosphatase and tensin homolog), leading to cell survival in cancers. 2, 5 In the absence of phosphoinositide 3-kinase/Akt signaling, FOXO3a localizes to the nucleus and initiates the transcription of its target genes PUMA and GADD45A. 4, 6 Furthermore, miRNA-155 has been shown to repress FOXO3a protein expression by directly interacting with its 3 0 -untranslated region. 7 In a study of breast cancer MCF-7 cells, FOXO3a was found to inhibit estradiol-dependent and estrogen receptor a-mediated cell proliferation. 8 Estrogen receptor b (ERb) acts as a tumor suppressor in many cancers and this is supported by knockout studies of the receptor in mice. [9] [10] [11] [12] Studies of ERb function in cell lines have revealed: (1) an anti-proliferative effect, [13] [14] [15] [16] (2) promotion of apoptosis via extrinsic pathway in castration-resistant basal epithelial cells in the prostates of aromatase knockout mice 17, 18 and (3) increased tamoxifen-induced cell death by upregulation of the pro-apoptotic gene Bik. 19 All the above findings suggest an apoptotic effect of ERb, although its molecular mechanism still remains unclear.
In the present study, we have examined the role of ERb in apoptosis. We found that the apoptotic function of ERb is mediated by upregulation of FOXO3a (a member of FOXO family). Upon transcriptional upregulation of FOXO3a, its downstream target PUMA is increased, leading to activation of the apoptosis machinery.
RESULTS

Expression of estrogen receptors in prostate cancer cell lines
ERb expression is reduced during progression of prostate cancer 20 and cells isolated from prostate cancer express low levels of ERb. 21 In the present study, we used the prostate cancer cell lines PC3, LNCaP and 22Rv1, the first two of which express low levels of ERb, whereas 22Rv1 cells are ERb negative (Figure 1a) . In LNCaP cells, ERb was detected in the nucleus by immunocytochemistry (Figure 1b) . Further, to understand how ERb causes apoptosis in prostate cancer cells, we developed a doxycycline-regulated expression system for ERb in PC3 and 22Rv1 cells. Following the removal of doxycycline, we observed a robust induction of ERb at both the mRNA and protein levels in 22Rv1 (Figures 1c and d ) and PC3 cells (Figures 1f and g ), respectively. Immunocytochemistry of ERb-expressing cells showed nuclear localization of the protein in 22Rv1 (Figure 1e ) and PC3 cells (Figure 1h ).
ERb induces apoptosis in prostate cancer cells Although several reports have shown an apoptotic effect of ERb in cancer cells, no detailed mechanism has been described. In order to study the apoptotic effect of ERb, we used the ERb-overexpressing PC3 and 22Rv1 cells. By using a flow-cytometry-based terminal transferase uridyl nick-end labeling (TUNEL) assay, we showed a representative plot where 12.5% of the cells expressing ERb were labeled with 5-bromo-2'-deoxyuridine compared with . Scale bars, 100 mm. All the experiments were performed n ¼ 3. (Figure 2a) . The quantification of TUNELpositive cells (n ¼ 3) showed a 9.6-fold increase of apoptosis in ERb-expressing cells compared with control cells (Figure 2b ). Furthermore, we showed that the sub-G1 peak, a feature of apoptotic cells, was increased in ERb-expressing PC3 (Figures 2c  and d ) and 22Rv1 cells (Figures 2e and f) compared with control (n ¼ 3). Moreover, analysis of annexin V using fluorescenceactivated cell sorting of PC3 cells showed an increase in annexin-V-positive cell population upon treatment with 3b-Adiol (5a-androstane-3b,17b-diol) compared with the vehicle-treated group (See Supplementary Figures S1A and B) .
1.3% in control cells
To estimate tumor-based apoptosis, we analyzed the xenografts from a previous study (Dey et al. 14 ) . Briefly, we used athymic nude mice to grow subcutaneous xenografts of PC3-control and PC3-ERb cells. The cells (2 Â 10 5 per 100 ml in 1:1 cells:matrigel) were injected into the flank of the mice and visible tumors developed after 40 days (Figure 3a ). There was a reduction in ki67 staining in ERb-expressing tumors (Figure 3b ). The inset in Figure 3b shows apoptotic bodies (arrows) in ERb-expressing tumor, whereas none was observed in control tumors. Furthermore, there was a higher frequency of TUNEL staining in tumors expressing ERb compared with control tumors (Figure 3c ). The apoptotic index (number of apoptotic cells/total number of cells Â 100%) showed an approximately threefold increase in TUNEL-positive cells expressing ERb compared with control cells (Figure 3d ).
Endogenously expressed ERb in LNCaP cells induces apoptosis after treatment with ERb-specific ligands The use of an ERb antibody made in our laboratory (ERb503 IgY chicken) allowed detection of nuclear staining in LNCaP cells by immunocytochemistry (Figure 1b) , and transfection with ERbspecific small interfering RNA (siRNA) resulted in a significant reduction in nuclear immunostaining of ERb, indicating the presence of ERb in these cells (Figure 4a ). We then sought to determine whether ERb-specific ligands could induce apoptosis by treating LNCaP cells with the 5a-dihydrotestosterone metabolite 3b-Adiol, a known endogenous ligand of ERb In order to understand the mechanism underlying the observed apoptosis, we investigated regulation of factors involved in the apoptotic pathway. We observed that the expression of the anti-apoptotic Bcl-2 was reduced in response to treatment of LNCaP cells with 3b-Adiol (Figure 5a ), in 22Rv1 cells stably expressing ERb and treated with 3b-Adiol ( Figure 5b ) and in PC3 cells stably expressing ERb (Figure 5c ). On the other hand, the proapoptotic factor Bax remained unchanged, except in 22Rv1 cells, which showed an increase in Bax expression (Figure 5b) . Furthermore, the ERb-specific ligands 3b-Adiol, DPN or 8b-VE2 (8-vinylestra-1,3,5 (10)-triene-3,17b-diol) decreased Bcl-2 expression in PC3 cells at a concentration of 10 nM (Figures 5d-f ).
Caspase-9 is the first caspase to respond to mitochondrialinduced release of cytochrome c, following changes in the activity of pro-apoptotic factors. We showed that cleaved caspase-9 (Asp330) was increased in PC3 cells treated with 3b-Adiol, DPN or 8b-VE2, strongly implying a role for ERb in apoptosis (Figures 5g-i) . The antibody used to detect cleaved caspase-9 (Cell Signaling Technology, Danvers, MA, USA; number 7237) recognizes the p37 subunit only, upon cleavage at the Asp330 site. Moreover, caspase 3/7 showed an increase in activity in the presence of 3b-Adiol or DPN in LNCaP cells (Figure 5j ).
ERb increases expression of PUMA independently of p53
We initially observed that prostate cancer cell lines stably expressing ERb are sensitive to serum starvation and show signs of apoptosis. This prompted us to look for apoptotic factors involved. After assaying expression of the most common factors involved in apoptosis, we found PUMA to be changed by ERb expression. Treatment of LNCaP cells with 3b-Adiol resulted in increased PUMA mRNA and protein levels (Figures 6a and b) . Treatment of PC3 cells with 3b-Adiol resulted in increased PUMA protein levels ( Figure 6c ). In addition, 22Rv1 cell lines stably expressing ERb showed increased levels of PUMA protein ( Figure 6d ). Knockdown of ERb using siRNA caused a decrease in PUMA expression, abolishing the 3b-Adiol-specific effect (Figures 6e-g ). As PUMA is an established p53 controlled gene, we investigated whether ERb regulates p53. To our surprise, we found that p53 expression was downregulated by 3b-Adiol in LNCaP cells (Figures 6h and i) and in 22Rv1-ERb stable cells (Figures 6j and k) .
As p53 is not upregulated by ERb, it became apparent that the regulation of PUMA must occur via an alternate pathway. PC3 cells are null for p53 expression, which further strengthens the idea that the regulation of PUMA by ERb is independent of p53. In a report by You et al., 4 FOXO3a was shown to upregulate PUMA independently of p53, upon withdrawal of cytokines or growth factors. FOXO3a's activity is regulated via phosphorylation by Akt (pT32, pS253 and pS315), whereupon it is exported from the nucleus and inactivated. 24 Reduction of threonine 32 phosphorylation leads to retention of active FOXO3a in the nucleus and upregulation of PUMA and GADD45A, which are direct targets of FOXO3a. 25 We found that total FOXO3a protein increased after treatment with ERb-specific ligands in LNCaP ( We also investigated the effect of 3b-Adiol on phosphorylation of Akt at Thr 308 and Ser 473 in LNCaP cells, and observed reduced phosphorylation at Thr 308 and reduced phospho c-raf, indicating less active Akt. However, phosphorylation of Akt at Ser 473 was unchanged from control. Moreover, total Akt (pan) remained unchanged (Figure 7k ).
ERb's regulation of FOXO3a is required for the upregulation of PUMA Finally, we wanted to examine whether ERb's regulation of FOXO3a could explain ERb's control of PUMA. We used siRNA to knock down expression of FOXO3a in LNCaP cells and PC3 cells (Figures 8a and b) . Here we showed that FOXO3a knockdown abolished the effect of 3b-Adiol on PUMA expression in LNCaP and PC3 cells. These data strongly indicate that FOXO3a expression is required for the regulation of PUMA by ERb. Moreover, combined knockdown of ERb and FOXO3a abolished the effect of 3b-Adiol on PUMA expression in PC3 cells (see Supplementary Figure S3 ).
To investigate whether ERb regulates FOXO3a in prostate epithelial cells in vivo, we used the ERb À / À mouse and compared it with the ERb þ / þ mouse. Deleting ERb (Figures 9b, d and f) 
DISCUSSION
The second estrogen receptor, ERb, was originally discovered in rat prostate in 1996. 26 Multiple studies during the last 16 years have described ERb as being anti-proliferative and proapoptotic. [16] [17] [18] [27] [28] [29] While the mechanism underlying ERb's antiproliferative effect has been described in several studies [14] [15] [16] the pro-apoptotic effect is less clear. We observed that high exogenous ERb expression levels obtained in breast and colon cancer cell lines are difficult to achieve in prostate cancer cell lines, which require an inducible system or expression at very low levels by using a weak promoter to avoid apoptosis. This prompted us to study the cause for increased apoptosis observed in prostate cancer cells upon ERb expression. ERb was detected in the nucleus of LNCaP, PC3 and 22Rv1 cell lines in agreement with a nuclear localization of ERb in PC3 cells, as reported by Leung et al. 21 The very low levels of ERb found in PC3 and LNCaP cells are consistent with the decrease in expression of ERb observed during progression of prostate cancer.
Furthermore, we observed that PC3 and 22Rv1 cells expressing exogenous ERb showed a larger sub-G1 peak in flow cytometry analysis and a higher number of apoptotic cells determined by TUNEL assay.
The three-dimensional xenograft model offers an in vivo-like environment compared with the two-dimensional cell culture dishes, and we demonstrated that, as expected, tumors expressing ERb showed an increase in apoptotic cells. When analyzing various pathways involved in apoptosis, we found the apoptotic factor PUMA to be induced by exogenous ERb expression in PC3 and 22Rv1 stable cells, and, also upon addition of 3b-Adiol, DPN or 8b- VE2 to PC3 and LNCaP cells, which are known to express low levels of endogenous ERb. 30, 31 Neither PC3 nor LNCaP cells responded to 17b-estradiol (E2) or 5a-dihydrotestosterone treatment as evident by unchanged levels of FOXO3a and PUMA protein (see Supplementary Figures S5A and B) . The non-responsiveness to E2 was an unexpected finding, indicating that the ERb/FOXO3A/ PUMA signaling pathway shows ligand specificity towards 3b-Adiol and the other tested ERb-specific ligands; interestingly, a similar ligand specificity has been described for the antiinflammatory action of ERb in the microglia. 32 Moreover, 5a-dihydrotestosterone was unable to regulate the expressions of FOXO3a and PUMA, indicating that this pathway is independent of androgen receptor. To investigate the involvement of ERa, we treated PC3 cells simultaneously with the ERa-specific ligand propyl pyrazole triol and with 3b-Adiol. We found that under these conditions, 3b-Adiol no longer increased the expression of PUMA, suggesting an antagonistic action of ERa, perhaps explaining why E2 was inactive (because of the activation of both receptors; see Supplementary Figure S5c ). In addition, GPR30 agonist G-1 alone demonstrated some degree of positive effect on PUMA regulation, but the effect was lost in the presence of 3b-Adiol (see Supplementary Figure S5c ). The exogenously expressed ERb is active in cell lines in the absence of ligand, whereas the low endogenous levels of ERb found in PC3 and LNCaP cells need ligand to be activated. We are currently unable to explain this difference in ligand activation between exogenously expressed ERb and endogenous ERb. Nonetheless, there is growing evidence that prostate tumors may maintain low level of ERb, which is not active in the absence of the natural agonist 3b-Adiol. Moreover, 3b-Adiol is reduced in cancer because of lower conversion from 5a-dihydrotestosterone, because of decreased 3b-hydroxysteroid dehydrogenase activity, 33 or a higher metabolism of 3b-Adiol by 7a-hydroxylase (CYP7B1), a member of the cytochrome P450 superfamily of enzymes. 34 The mechanism of ERb-induced apoptosis in prostatic cancer apparently involves the pro-apoptotic PUMA, a well-characterized target gene of p53. 35 However, surprisingly, the p53 levels were not changed or rather decreased following ERb activation and, thus, p53 regulation could not explain the induction of PUMA. This was further supported by experiments with PC3 cells, which, upon activation of ERb, respond by upregulating PUMA, although these cells lack p53. This prompted us to look for an alternate pathway. It is known that PUMA can be induced by the withdrawal of growth factors and this mechanism is dependent on activation of FOXO3a through reduced phosphorylation by Akt. 4 Although we found that phospho-Akt (pT308) was reduced by the activation of ERb, phosphorylation of FOXO3a was unchanged by ERb expression, whereas both mRNA and protein levels of FOXO3a were increased. To establish the importance of the observed regulation of FOXO3a mRNA and protein levels for subsequent induction of PUMA, we used siRNA to knock down FOXO3a expression, resulting in a loss of PUMA regulation by ERb. Our present study indicates that ERb-stimulated upregulation of FOXO3a produces enough unphosphorylated, active FOXO3a protein to induce the expression of PUMA. It is interesting to note that PUMA has been shown to be acutely downregulated by estrogen in breast cancer cell lines, while, on the other hand, being transcriptionally upregulated by tamoxifen independent of p53 status, 36 indicating that estrogen receptors regulate FOXO3a and PUMA also in other tissues than prostate.
The pathway connecting ERb to FOXO3a is an unexpected and novel finding helping to explain some of our previous studies with breast, colon and prostate cancer cells where we have shown that ERb regulates p45
Skp2 , p21 and p27. 14, 16, 37, 38 These are all known target genes of FOXO3a, and ERb might indirectly regulate these genes via FOXO3a.
In summary, this is the first study demonstrating that induction of FOXO3a expression has a role in its effect on apoptosis besides the well-known post-translational modification of FOXO3a by phosphorylation. We identified two estrogen response element (ERE) half sites and an AP1 site downstream of the FOXO3a gene, and showed that this sequence upregulates FOXO3a transcription (see Supplementary Figure S6 ). Furthermore, ERb À / À mice showed a strong decrease in expression of FOXO3a. In addition, we found ERb and FOXO3a to be co-expressed in BPH, but a strong reduction of both factors in higher grade prostate cancer. Because of the low number of cancer samples used in this study, we cannot conclude that high Gleason grade prostate cancer generally loses ERb expression. Some studies suggest that ERb might be involved in driving an aggressive prostate cancer phenotype. 39, 40 It is possible that the contradictory findings may depend on differences in function of ERb splice variants that are also knocked down by ERb siRNA and react with an N-terminal antibody. Further studies with a larger number of clinical samples will help to increase our understanding of ERb's function in prostate. An overview of the proposed novel ERb/FOXO3a/PUMA model is outlined in Figure 11 . Exploration of this newly discovered pathway connecting ERb to FOXO3a and PUMA might help to develop new targeted drugs in the clinical management of prostate cancer.
MATERIALS AND METHODS
Reagents, cell culture and generation of stable ERb-expressing cells
The PC3, LNCaP and 22Rv1 cell lines were obtained from the American Type Culture Collection and maintained in RPMI-1640 (Invitrogen Inc., Carlsbad, CA, USA) medium supplemented with 10% fetal bovine serum 
Construction of an inducible system for ERb
Prostate cancer cell lines LNCaP and PC3 express minute amounts of endogenous ERb, and 22Rv1 expresses none. To elucidate the molecular mechanism behind the apoptotic function of ERb, a transposon-based overexpression system was used to stably transfect PC3 and 22Rv1 prostate cancer cells with the ERb constructs or with empty vector as a control. All plasmids were transfected using Lipofectamine 2000 (Invitrogen Inc.) in Opti-Mem medium (Invitrogen Inc.) according to the manufacturer's protocol. Complete RPMI-1640 medium with 10% fetal bovine serum medium was added after 6 h of incubation with the transfection reagents. Further details about the transposon-based overexpression system can found in Dey et al. 14 
Protein extract preparation
Nuclear extracts from PC3, 22Rv1 and LNCaP cells were prepared as described previously. 41 To prepare whole-cell extracts, the cells were washed twice with phosphate-buffered saline (PBS), lysed in 10 times packed cell volume of lysis buffer (0.1% Nonidet P-40, 250 mM KCl, 5 mM Hepes, pH 7.9, 10% (vol/vol) glycerol, 4 mM NaF, 4 mM sodium orthovanadate, 0.2 mM EDTA, 0.2 mM EGTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, protease inhibitor cocktail and PhosStop (Roche, Indianapolis, IN, USA)) for 30 min on ice and then centrifuged at 14 000 g for 10 min.
Western blotting and antibodies
Twenty micrograms of protein were loaded on an SDS-polyacrylamide gel electrophoresis 10% Bis-Tris gel with Tris running buffer 42 and transferred to a nitrocellulose membrane after electrophoretic separation. The membranes were blocked with 5% non-fat powdered milk in 0.1% Tris-buffered saline and Tween 20 buffer. The blots were then probed with various primary antibodies. The primary antibodies were used at dilutions of 1:200-1000, and the secondary antibody was used at a dilution of 1:10,000. More details and lists about the antibodies can be found in Supplementary Table 1. RNA extraction and real-time PCR
RNA extraction was performed with Qiagen mRNA extraction kit (Qiagen Sciences, Fredrick, MD, USA) according to standard protocol. cDNA was synthesized from 1 mg of total RNA with First Strand System according to standard protocol (Invitrogen Inc.). Real-time PCR was performed with SYBR Green I dye master mix (Applied Biosystems, Foster City, CA, USA). The list of primers used can be found in the Supplementary Table 2 .
Apoptosis detection by TUNEL assay
The apoptotic cells were quantified for DNA fragmentation, by using an In-situ Cell Death Detection kit, Fluorescein (Roche Diagnostics GmbH, Mannheim, Germany), according to the manufacturer's protocol. In brief, excised tumor tissues were fixed in 4% paraformaldehyde, dehydrated and embedded in paraffin. Paraffin-embedded tissues were cut into 5-mm thick sections. The sections were deparaffinized and rehydrated according to standard protocol. The tissue sections were then antigen retrieved at 0.1 M citrate buffer for B5 min in a pretreatment module (pH 6.0) and then rinsed twice in PBS. The slides were then treated with 50 ml of 'TUNEL reaction mixture' and incubated at 37 1C for 60 min The slides were then rinsed 3 Â with PBS. Negative and positive slides were included. For negative slides, only 50 ml of 'Label solution' (without terminal transferase enzyme) was used and for positive slides, the slides were treated with DNase I before proceeding with treating with 'TUNEL reaction mixture'. For microscopic image capture, four high-power fields were randomly selected and the apoptotic index was calculated as equal to number of positive cells/total number of cells Â 100%.
Annexin V assay
Cells were plated on a six-well plate and treated for 12 h with ERb-specific ligand (3b-Adiol). For flow-cytometry-based analysis, FlowCollect annexin red kit from Millipore (Billerica, MA, USA) was used. Sample collection and annexin staining of the cells were done according to manufacturer's instruction. Briefly, cells were washed with 1 Â PBS, then with 1 Â assay buffer. The cells were then incubated for 15 min with annexin VCF674 and the DNA was stained with propidium iodide for another 15 min. The stained samples were then analyzed using FACS Aria II (BD Biosciences, San Jose, CA, USA).
Survival assay
For survival assays, 5000 cells were seeded on a 60-mm dish. The cells were treated with ligands or vehicle for 24 h in 1% serum stripped media. After 24 h treatment, the cells were grown for another 20 days in a complete medium. The cells were then washed twice with cold PBS and fixed in cold methanol for 10 min. The cells were then stained with 0.25% crystal violet in 50% methanol. The plates were then washed with water, air-dried and photographed.
Human samples Immunohistochemistry and immunofluorescence of knockout mice and tumor xenograft For immunohistochemistry, 5 mm sections from 12-month-old ventral prostate of wild-type and ERb knockout (ER À / À ) mice were used. ERb was detected using an antibody raised in chickens (ERb 503). Slides were deparaffinized with 3 Â xylene and rehydrated through ethanol gradient. Antigen retrieval was performed in pretreatment module in 0.01 mol/l citric acid (pH 6.0) for 15 min followed by 0.5% Triton-X treatment for Figure 11 . The slides were then stained in 3,3 0 -diaminobenzidine and counterstained with Mayer hematoxylin (Sigma) before dehydration through ethanol, and mounted in Pertex (Histolab, Goteborg, Sweden). For FOXO3a, antigen retrieval was performed in pretreatment module for 7 min. Endogenous peroxidase activity was blocked as mentioned before and then blocked in 3% BSA and 0.1% NP40 for 10 min at room temperature. For FOXO3a, primary antibody was diluted 1:800 (Santa Cruz, Dallas, TX, USA) in 3% BSA and 0.1% NP40, and incubated overnight at 4 1C. Sections were then washed consecutively in 0.1% NP40 for 30 min and with PBS, followed by incubation with a Rabbit-on-Rodent HRP polymer (Biocare Medical, Concord, CA, USA) for 30 min at room temperature. Sections were then washed consecutively in 0.1% NP40 for 30 min and with PBS for 10 min. The slides were then stained in 3,3
0 -diaminobenzidine and counterstained with Mayer hematoxylin (Sigma) before dehydration through ethanol, and mounted in Pertex (Histolab).
To examine the number of proliferating cells in ERb-expressing tumor xenografts, immunohistochemistry with a ki67 antibody was performed. The tumor tissues were processed similarly to the knockout mouse sections. The primary antibody was used at a concentration of 1:100 dilutions.
For immunofluorescence of mouse ventral prostate sections, the tissue was processed as for immunohistochemistry. The sections were treated with ERb and FOXO3a antibodies and incubated overnight at 4 1C. Next day, the sections were washed in 3 Â PBS for 5 min and secondary antibodies were added (ant-chicken-FITC (A-11039; Life Technologies, Grand Island, NY, USA) for ERb and anti-rabbit-Texas Red (Ti-1000; Vector Labs) for FOXO3a for 1 h. The sections were then washed in 3 Â PBS for 5 min and mounted with Vectashield mounting media with DAPI (4',6-diamidino-2-phenylindole, H-1200; Vector Labs). Images were captured with Olympus BX51 microscope fitted with XM10 and BP25 cameras.
Immunocytochemistry
Immunostaining was performed as described previously. 43 In brief, the cells were grown on autoclaved coverslips. Twenty-four hours after treatment, the cells were washed twice with PBS. The cells were treated with 4% formalin in PBS followed by 0.25% Triton-X-100. The cells were then blocked with 3% BSA. The coverslips containing the cells were placed in a humidified chamber, and primary antibodies were added at a 1:50-200 dilution. The cells were incubated at 37 1C for 1 h. After incubation, the cells were washed three times with PBS. Fluorescence-labeled (Texas red or Cy3 dye) secondary antibody was added at a 1:1000 dilution and incubated at 37 1C for 1 h. The cells were further washed five times with PBS and nuclear stained with DAPI for 1 min. The coverslips were then mounted on a slide with fluorescence mounting solution (Dako, Carpinteria, CA, USA). Fluorescent images were captured using an Olympus BX51 microscope fitted with XM10 and BP25 cameras. The ERb (503) primary antibody used for immunocytochemistry were made at the Karolinska Institutet, Stockholm, Sweden. 
Statistics
The values are expressed as the mean with 95% confidence intervals. An unpaired two-tailed Student's t-test was used to compare the differences between two groups. The significance is presented as *Po0.05, **Po0.005 and ***Po0.001, and non-significant differences are presented as NS.
